Immunotherapy and molecular tumor therapy
The Tumor Center is divided into eleven organ tumor centers. In order to take account of the further development of oncology, these are supplemented by two competence networks, which serve as cross-sectional services. By establishing these two competence networks, our tumor center has entered a new era of oncology in order to guarantee our patients individual, interdisciplinary care based on the latest findings.
The networks interact closely with the individual organ tumor centers and develop guidelines for diagnostics, therapy and side effect management. They serve as a coordination point for clinical and translational research projects and have both established their own tumor board.
Immunotherapy
The Immunotherapy Board takes place once a month. Here, immunotherapy patients are discussed individually by the specialists from various disciplines involved and therapies are determined. Great care is taken to ensure that the side effects of the therapy are controlled or avoided. In addition, the new immune strategies should be cleverly combined with existing therapeutic approaches in order to achieve maximum effect.
Patients benefit from the constantly updated shared knowledge and clinical expertise, as therapeutic strategies are continuously adapted to international standards. In close cooperation with the referring physicians in the region, we also strive to participate in innovative studies.
Consultation hours
Monday: Prof. Alfred Zippelius
Friday: Dr. Heinz Läubli
Registration
University Hospital Basel
Clinic for Oncology
Petersgraben 4
4031 Basel
Phone +41 61 265 50 74 and +41 61 265 50 59
onkologie@usb.ch
Management
Prof. Heinz Läubli
Leitender Arzt / Leitung Klinische Forschung
medizinische Onkologie FMH, allgemeine Innere Medizin FMH, Mitglied Tumorzentrum, Forschungsgruppenleiter Tumorimmuntherapie, DBM und DKF
Team
Dr. Kathleen Jahn
Kaderärztin, Stv. ärztliche Leitung interventionelle Pneumologie
Pneumologie
Prof. Alfred Zippelius
Co-Chefarzt
Medizinische Onkologie FMH, Mitglied Tumorzentrum, Leiter Labor Tumorimmunologie
Molecular therapy
Since September 2015, the Molecular Tumor Board has been the first of its kind in Switzerland to take place every two weeks. Treatment decisions are made here based on the genomic sequencing of tumors. The sequencing data is interpreted by molecular pathologists, biologists and medical geneticists, and treatment decisions are made together with medical oncologists and haematologists.
The well-established tumor board discusses patient findings from various specialist disciplines. For example, benign diseases from rheumatology are also discussed in order to utilize the interdisciplinary nature of the board.
Consultation hour
PD Dr. med. Dr. phil. Sacha Rothschild
Thursday: 2.30 - 4.30 pm
Registration
University Hospital Basel
Clinic for Oncology
Petersgraben 4
4031 Basel
Phone +41 61 265 50 74 and +41 61 265 50 59
onkologie@usb.ch
Management
PD Dr. Benjamin Kasenda
Leitender Arzt
Innere Medizin Hämatologie/Onkologie und FA medizinische Onkologie
Gastrointestinale Tumore
Members
Prof. Dr. med. Dr. phil. nat. Karl Heinimann
Stv. Ärztlicher Leiter
Medizinische Genetik
Prof. Matthias Matter
Leitender Arzt und Fachbereichsleiter Molekularpathologie
Pathologie
Tel. +41 61 328 64 71